Pulmonary Hypertension Clinical Trial
Official title:
Systematic Assessment of Pulmonary Artery Haemodynamics Using Wave Intensity Analysis
The mechanism governing how blood flows from the heart to the lungs depends on many factors
including the pumping function of the right ventricle, properties of the arteries that carry
the blood from the right ventricle to the lungs (pulmonary arteries), and the lungs
themselves.
Under normal conditions the pressure in the pulmonary arteries is well controlled and
significantly lower than in the systemic circulation, however there are a number of
conditions that lead to abnormally high pressures and significant morbidity and mortality.
However different patients respond differently to similarly elevated pressures, leading
doctors to believe that there must be differences in either the right ventricles, the
properties of the arteries, or the lungs themselves. It can be difficult to determine the
relative contributions of each of these factors on blood flow because their effects are
superimposed on each other.
One approach that has been used to look at this in other parts of the circulation (including
in the systemic circulation and the coronary arteries) is to measure simultaneous pressure
and flow, and apply a technique called wave intensity analysis (WIA). This technique can
amongst other things, quantify the separate effects of wave reflection and the 'reservoir
function' (or compliance) of the arteries, and in the systemic circulation WIA has increased
the understanding of the mechanisms behind hypertension and the physiological changes of
ageing. The pulmonary arteries are accepted to be very different from the systemic
circulation and the mechanisms behind pulmonary hypertension are thought to be very
different to those of systemic hypertension.
This protocol aims to determine the major influences on blood flow in the pulmonary arteries
in health and disease, to help to understand why some patients are affected more than others
by elevated pulmonary pressures.
Purpose Currently best clinical practice for the investigation of pulmonary hypertension
(raised pulmonary pressures) involves patients attending the catheter laboratory and
catheters being passed under fluoroscopic guidance via the femoral vein to measure right
heart pressures (and generally also via the femoral artery and aorta to measure left sided
pressures). Wave intensity analysis using simultaneous pressure and flow measurements gives
additional information about the upstream and downstream effects on haemodynamics, and we
propose will lead to a more detailed assessment of the influences both causing and
exacerbating pulmonary hypertension. Until recently it has not been possible to assess these
effects formally: the standard technique measures only local pressure.
Design This protocol will involve passing catheters as per usual practice into the pulmonary
arteries and aorta. A Combiwire (a standard pressure and flow measurement wire which has
been available commercially and used worldwide for the past 5 years for making physiological
measurements in the coronary arteries) will then be advanced approximately 1cm beyond the
end of the catheter. Participants will have the usual clinical protocol of left and right
heart catheterisation (and coronary angiography if clinically indicated) and the
simultaneous pressure and flow measurements will be made in addition. Participants will also
have noninvasive imaging (echocardiography and, if clinically indicated, cardiac MRI) and
serum biochemical measures, as per usual clinical practice. They will also undergo
cardiopulmonary exercise testing to assess their lung and cardiac capacity.
Recruitment The investigators will recruit patients with pulmonary hypertension from the
National Pulmonary Hypertension Service who are awaiting right and left heart
catheterisation studies as part of their routine diagnostic work up. Patients with normal
pulmonary pressures will be recruited from patients who are on the waiting list awaiting
routine cardiac catheterisation for the investigation of shortness of breath and chest pain.
Recruitment will involve a discussion with the patient and printed material that the patient
can refer to. They will be fully aware of the additional measurements being made, and no
therapeutic promises will be made.
Development of Research Proposal Interventional cardiologists, pulmonary hypertension
specialists, clinical scientists and basic scientists have been involved with the
development of this protocol. All members have been involved in critiquing the proposal. The
investigators have also consulted patients who have been involved in previous research
conducted during angiography regarding the number of hospital visits and additional time
required during the procedure for data collection.
Consent All patients will be consented for the study by the research Fellow who will be a
Cardiology SpR (MBBS, MRCP) or Pulmonary Hypertension Specialist. She will be able to assess
capacity and understand the ethical principles underpinning informed consent.
Risks, burdens and benefits The risk of using pressure and flow wires: The wires will be
advanced approximately 1cm outside the guide catheter that is used in routine clinical
practice. In the pulmonary artery the wire will be positioned approximately 15cm more
proximal than where the balloon is inflated during conventional pulmonary capillary wedge
pressure measurement. In a recently published study of >7000 patients undergoing right heart
catheterisation, there was only one incidence of pulmonary artery dissection. Damage to the
arteries will be minimised by using an experienced interventional cardiologist to perform
the procedures. The investigators have extensive knowledge in making these measurements
resulting in minimal risk to the patient. To date no patient has had an adverse event
secondary to the use of the pressure and flow wires in either the pulmonary arteries, aorta
or coronary arteries. A pilot safety and feasibility study in 23 patients undertaken at the
Royal Brompton Hospital in both normal subjects and those with pulmonary hypertension of
various aetiologies showed that measurements of pressure and flow using Combiwires in the
pulmonary arteries are possible in patients studied and there were no complications.
Confidentiality The Caldicott Principles for use of identifiable data will be used. In
accordance with University and NHS policy, to ensure satisfactory integrity both of research
data and confidential patient information, the procedural data will be stored in anonymised
form on a fully archived hard disk drive, with additional backup on long term optical
storage media, while patient identifiable data will be stored on computers located within
the NHS facility. Linkage between them will be in the form of paper records, which will be
retained within the NHS premises. If confidentiality needs to be broken we will seek advice
from the local ethics committee.
Conflict of Interest We have no conflict of interest. The patients involved in this study
will be informed via an information leaflet of the results and what they mean at the end of
the study.
;
Observational Model: Case Control, Time Perspective: Cross-Sectional
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT01950585 -
Hydroxyurea in Pulmonary Arterial Hypertension
|
Early Phase 1 | |
Completed |
NCT00527163 -
Role of Nitric Oxide in Malaria
|
||
Completed |
NCT03649932 -
Enteral L Citrulline Supplementation in Preterm Infants - Safety, Efficacy and Dosing
|
Phase 1 | |
Recruiting |
NCT04554160 -
Arrhythmias in Pulmonary Hypertension Assessed by Continuous Long-term Cardiac Monitoring
|
||
Enrolling by invitation |
NCT03683186 -
A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension
|
Phase 3 | |
Completed |
NCT01894035 -
Non-interventional Multi-center Study on Patients Under Routine Treatment of Pulmonary Arterial Hypertension (PAH) With Inhaled Iloprost Using I-Neb as a Device for Inhalation
|
||
Not yet recruiting |
NCT04083729 -
Persistent Pulmonary Hypertension After Percutaneous Mitral Commissurotomy
|
N/A | |
Completed |
NCT02216279 -
Phase-II Study of the Use of PulmoBind for Molecular Imaging of Pulmonary Hypertension
|
Phase 2 | |
Terminated |
NCT02243111 -
Detecting Pulmonary Arterial Hypertension (PAH) in Patients With Systemic Sclerosis (SSc) by Ultrasound
|
N/A | |
Terminated |
NCT02246348 -
Evaluating Lung Doppler Signals in Patients With Systemic Sclerosis (SSc)
|
N/A | |
Completed |
NCT02821156 -
Study on the Use of Inhaled NO (iNO)
|
N/A | |
Recruiting |
NCT01913847 -
Safety and Efficacy Study of HGP1207 in Patients With Pulmonary Hypertension
|
Phase 3 | |
Completed |
NCT06240871 -
Contrast Enhanced PA Pressure Measurements
|
||
Completed |
NCT01615484 -
Ex-vivo Perfusion and Ventilation of Lungs Recovered From Non-Heart-Beating Donors to Assess Transplant Suitability
|
N/A | |
Completed |
NCT02377934 -
Evaluation of Radiation Induced Pulmonary Hypertension Using MRI in Stage III NSCLC Patients Treated With Chemoradiotherapy. A Pilot Study
|
||
Recruiting |
NCT01091012 -
Effectiveness of the Vasodilator Test With Revatio, Made in Patients With Acute Pulmonary Hypertension
|
Phase 3 | |
Completed |
NCT00739375 -
The Effect of Blood Flow in the Maturing Arteriovenous Access for Hemodialysis on the Development of Pulmonary Hypertension.
|
Phase 1 | |
Completed |
NCT02275793 -
The Regulation of Pulmonary Vascular Resistance in Patients With Heart Failure
|
||
Completed |
NCT01463514 -
Noninvasive Determination of Cerebral Tissue Oxygenation in Pulmonary Hypertension
|
N/A | |
Completed |
NCT01484899 -
Smoking: a Risk Factor for Pulmonary Arterial Hypertension?
|
N/A |